Integra LifeSciences (IART)
(Real Time Quote from BATS)
$17.29 USD
-0.21 (-1.20%)
Updated Oct 2, 2024 10:52 AM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
Price, Consensus and EPS Surprise
IART 17.29 -0.21(-1.20%)
Will IART be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for IART based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IART
TransMedics (TMDX) Moves 10.1% Higher: Will This Strength Last?
Integra's (IART) Q2 Earnings and Revenues Top, Margins Down
IART: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics
Integra LifeSciences (IART) Q2 Earnings and Revenues Surpass Estimates
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Other News for IART
Integra LifeSciences price target lowered by $4 at Citi, here's why
Unveiling 10 Analyst Insights On Integra Lifesciences
Integra Lifesciences Holdings Corp (IART) Shares Down 3.75% on Sep 25
The Top Five short crowded stocks in each U.S. sector
Wall Street Breakfast: The Week Ahead